FindTrial
Sign In

Comparing two Drugs for Reversing Muscle Relaxation After Surgery in Cancer Patients

A prospective randomized comparative study to evaluate the efficacy of Sugammadex vs Neostigmine for reversal of Rocuronium induced neuromuscular blockade in patients undergoing onco surgeries - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082661
Enrollment
70
Registered
2025-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D249- Benign neoplasm of unspecified breast Health Condition 2: C509- Malignant neoplasm of breast of unspecified site Health Condition 3: C269- Malignant neoplasm of ill-definedsites within the digestive system Health Condition 4: C55- Malignant neoplasm of uterus, partunspecified

Interventions

Intervention1: INJ Sugammadex: a single intravenous (IV) dose of INJ Sugammadex (2.0 mg/kg) Control Intervention1: INJ Neostigmine plus INJ Glycopyrrolate: a single IV dose of INJ Neostigmine 0.05mg

Sponsors

Dr Eashwar S M
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients consenting to participate in the study. ASA Grade I & II patients. BMI less than 30kg/m2

Exclusion criteria

Exclusion criteria: Patient not consenting to the study. ASA III & IV Patients with neuromuscular disorders. Hypersensitivity/ allergic history to drugs.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of Sugammadex versus Neostigmine for reversal of NMB induced by Rocuronium.Timepoint: 5hours—

Secondary

MeasureTime frame
To compare the adverse effects of Sugammadex versus Neostigmine.Timepoint: 5 hours—

Countries

India

Contacts

Public ContactDr Punita priya S

kidwai memorial institute of oncology

namrang@gmail.com9880642830

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026